The access and use of GLP-1 receptor agonists in people with eating disorders in the UK: A mixed method study
Abstract
Objective: To explore the use, access, and motivations of individuals with eating disorders (EDs) attempting to access Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management in the UK.
Method:: A mixed-methods convergent parallel design was used. Eligible participants were aged 16+, had an ED, and had attempted to access GLP-1 RAs in the past two years. Seventy-two participants completed an online survey, with quantitative data analysed descriptively and qualitative data analysed thematically.
Results:: Ninety three percent (n=67) reported current or previous GLP-1 RA’s use and most common motivations were weight loss and binge eating reduction. The most frequent prescriber was online pharmacies (n=52, 74.3%). When prescribed, two thirds were asked about an ED but did not disclose this, one quarter were not asked about EDs. Thirty seven percent (n=25) of participants who received medication did not meet BMI prescription requirements and the approximately half did not receive ongoing monitoring. Qualitative themes found that motivations for using GLP-1 RAs were guided by ED cognitions and recovery, and uncertainty emerged surrounding intentions of long-term use.
Conclusion:: Despite screening of ED’s and BMI being recommended, most participants in this study obtained GLP-1 RAs for weight loss with little ongoing monitoring, suggesting the need for more robust regulation.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.